Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ritlecitinib in children aged 6 to under 12 years with severe alopecia areata
CTR20253559Phase 3Active
- Sponsor
- Pfizer
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Started Sep 2025; status: active.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20253559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253559.